secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001829126-26-001755
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc to present Phase 1 dose-escalation data from NEO212 trial on March 4 call
-------------------------------------------------------------------------------

- Investor conference call scheduled for March 4, 2026 at 9:00 a.m. ET to present initial Phase 1 dose-escalation results from NEO212-01 trial.
- Phase 1 portion evaluated oral NEO212 in CNS malignancies; data includes safety, toxicity, PK, and regulatory next steps.
- Featured participants: Dr. Henry Friedman (Duke), Dr. Alexandra Miller (NYU Langone), plus NTHI management.
- NEO212 is a proprietary bioconjugated temozolomide platform with FDA Fast-Track and IND status for CNS cancers.
- No specific data disclosed in this release; full presentation will occur on the call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626001755/0001829126-26-001755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626001755/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-001755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer